// App-Quantinova.ai

9044 : Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.

Researchers

Presenter

  • Daniel Shao-Weng Tan

Principal Investigators

  • James Chih-Hsin Yang

  • Natasha B. Leighl

  • Gregory J. Riely

  • Lecia V. Sequist

  • Enriqueta Felip

  • Takashi Seto

  • Juergen Wolf

  • Susan Elizabeth Moody

  • Kenneth Adams

  • Shu-Fang Hsu Schmitz

  • Eugene Y. Tan

  • Dong-Wan Kim

Medical Centers

  • National Cancer Centre Singapore, Singapore, Singapore

  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Massachusetts General Hospital, Boston, MA

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Kyushu Cancer Center, Fukuoka, Japan

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

Locations

  • Canada

  • Taiwan

  • Japan

  • Singapore

  • Spain

  • Germany

  • Switzerland

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

  • Threonine at amino acid position 790

Drug/Treatment

  • L-Tyrosine

  • EGF816

Outcome

  • Unknown

Study Design

  • Adaptive

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02108964

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved